Teprotumumab for Active Thyroid Eye Disease
N Engl J Med
.
2020 May 14;382(20):1959.
doi: 10.1056/NEJMc2002754.
Authors
Jonathan C P Roos
1
,
Hanna I Hyry
2
,
Rachna Murthy
3
Affiliations
1
Moorfields Eye Hospital, London, United Kingdom
[email protected]
.
2
University of Cambridge, Cambridge, United Kingdom.
3
Cambridge University Hospitals, Cambridge, United Kingdom.
PMID:
32402171
DOI:
10.1056/NEJMc2002754
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Graves Ophthalmopathy*
Humans
Substances
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
teprotumumab